Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05680831
Other study ID # IRB# 21-3193
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 13, 2022
Est. completion date February 1, 2025

Study information

Verified date January 2023
Source Environmental Protection Agency (EPA)
Contact Martin W Case, B.S.
Phone 919-966-6211
Email case.martin@epa.gov
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Purpose: The primary purpose of this study is to measure pulmonary function, symptoms, and pulmonary inflammatory responses in healthy young adults during and immediately after exposure to a low concentration of ozone (0.070 ppm) or clean air for 6.6 hours while undergoing moderate intermittent exercise. This concentration is the current EPA NAAQS standard for ozone.


Description:

Potential health effects of ozone have been extensively studied over decades at various levels of exposure concentration and for varying time periods in young healthy adult subjects. Effects of ozone have been well documented particularly for decrements of lung function and an influx of neutrophils and other markers of pulmonary inflammation. The majority of those studies were done at ozone concentrations between 0.12 and 0.40 ppm, considerably higher than the current EPA NAAQS ozone standard of 0.070 ppm, and at exposure durations of two hours, even though the current standard is an 8-hour standard. However, a small number of studies have assessed changes in lung function following exposure to low levels of ozone for several hours. These latter studies have shown that exposure to ozone for 6.6 hours at concentrations between 0.06 and 0.08 ppm causes mild reversible decrements in lung function (1.7-10%) as measured by forced vital capacity (FVC) and forced expired volume at 1 s (FEV1) immediately after exposure in healthy young adults. In addition, in one study an increase in ozone-induced neutrophils was seen in induced sputum following exposure to 0.06 ppm ozone (8) and in bronchoalveolar lavage fluid) following exposure to 0.08 ppm ozone (9). The EPA is considering whether the current ozone NAAQS standard at 0.070 is protective and has asked EPA researchers to conduct a study similar to those done at 0.06 and 0.08 ppm.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date February 1, 2025
Est. primary completion date February 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: 1. Healthy men and women between 18 and 35 years of age. 2. Physical conditions allowing sustained moderate exercise for 6.6 hours. 3. Normal lung function (NHANES III): 1. FVC > 80 % of that predicted for gender, ethnicity, age and height. 2. FEV1 > 80 % of that predicted for gender, ethnicity, age and height. 3. FEV1/FVC ratio > 80 % of predicted values 4. Oxygen saturation > 94 %. 5. Total symptom Score no greater than 20 (out of a possible 60-see accompanying score sheet) with a value no greater than 3 for any one score. No more than one score may be equal to 3. Exclusion Criteria: 1. Individuals with a diagnosis of COVID-19 and/or hospitalized for COVID-19. 2. Individuals who are not "up to date," [meaning a person has received all recommended COVID-19 vaccines, including any booster dose(s) when eligible with their COVID vaccines as defined by the CDC.] 3. A history of acute and chronic cardiovascular disease, chronic respiratory disease, diabetes,rheumatologic diseases, immunodeficiency state. 4. An acute respiratory illness within 4 weeks. 5. Subjects who are asthmatic or have a history of asthma. 6. Allergic to chemical vapors or gases. 7. Any allergic symptoms during the time of participation in the study 8. Female subjects who are currently pregnant, attempting to become pregnant or breastfeeding 9. Subjects currently taking mega doses of vitamins and supplements, homeopathic/naturopathic medicines or medications which may impact the results of the ozone challenge or interfere with any other medications potentially used in the study (to include systemic steroids and beta blockers). Medications not specifically mentioned here may be reviewed by the investigators prior to a subject's inclusion in the study. 10. Current and past smokers within 2 years, or subjects with a smoking history of at least a pack of cigarettes a day for more than 10 years over your lifetime. This includes vaping, hookah,and e-cigarettes. 11. Uncontrolled hypertension (> 140 systolic, > 90 diastolic). Blood pressure readings equal to or greater that 140 Systolic and equal to or greater that 90 diastolic. 12. Subjects who do not understand or speak English 13. Unspecified illnesses, which in the judgment of the investigator might increase the risk associated with ozone inhalation challenge or exercise, will be a basis for exclusion. Temporary exclusion criteria: 1. Individuals who have had an acute respiratory illness within 4 weeks. 2. Individuals who have active allergies. 3. Individuals that have engaged in strenuous exercise within 24 hours of any study visit. 4. Individuals unable to avoid drinking alcohol for 24 hours prior to all study visits. 5. Individuals who have been exposed to smoke and fumes for 24 hours before all visits. 6. Individuals that have used an ozone-based home air purifier for 24 hours before all visits. 7. Individuals that have eaten or drank anything for 2 hours prior to the sputum training/screening day visit. 8. Individuals should avoid caffeine for 12 hours prior to all study visits. 9. Individuals should refrain from all over the counter anti-inflammatory agents including those for allergies, and anti-inflammatory drugs or antioxidants for a period of one week prior to the train and to the exposure. 10. Individuals that have been exposed to or have consumed any agent or have undertaken any activity within 24 hours of any study visit that the investigators believe may compromise the results of the study. -

Study Design


Intervention

Biological:
0.070 ppm ozone concentration
The concentration of ozone a subject will randomly receive on a visit for 6.6 hours in a controlled atmospheric chamber while performing moderate intermittent exercise.
Clean air (0.0 ppm ozone)
Same subject will randomly receive clean air on another visit separated by at least one week for 6.6 hours in the same controlled atmospheric chamber while performing moderate intermittent exercise.

Locations

Country Name City State
United States EPA Human Studies Facility Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Martin W. Case University of North Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary FVC forced vital capacity measured (pre) before starting 6.6 hours of exercise
Primary Change in FVC change in forced vital capacity change measured (post) immediately after 6.6 hours of exercise
Primary FEV1 forced expiratory volume in 1 second measured (pre) before starting 6.6 hours of exercise
Primary Change in FEV1 change in forced expiratory volume in 1 second change measured (post) immediately after 6.6 hours of exercise
Secondary % neutrophils collected by induced sputum Subjects will breathe a hypertonic saline solution from an ultrasonic nebulizer through a mouthpiece at saline concentrations of 3%, 4%, and 5%. After each inhalation period subjects be asked to cough up the expectorate in a sterile cup for analysis of neutrophil cells influx baseline: training/qualification day
Secondary change in % neutrophils collected by induced sputum Subjects will breathe a hypertonic saline solution from an ultrasonic nebulizer through a mouthpiece at saline concentrations of 3%, 4%, and 5%. After each inhalation period subjects be asked to cough up the expectorate in a sterile cup for analysis/quantitation of neutrophil cells influx 18 hours post exposure
See also
  Status Clinical Trial Phase
Completed NCT04892004 - Symptom Recognition Improves Self-care in Patients With Heart Failure. N/A
Recruiting NCT06446999 - Yoga-Based Breathing Exercise, Colorectal Cancer Surgery N/A
Not yet recruiting NCT05505188 - Predictive and Impact of Pain After 6 Months of Radiotherapy, in Head and Neck Cancer N/A
Completed NCT04864600 - CANDLE - A Study of Acute Health Effects of Exposure to Particles Generated by Candles N/A
Completed NCT03336177 - Understanding Low Gynecological Cancer Delay and Help-seeking Behavior in Older Patients.
Completed NCT06395025 - Blinded User Study for the Evaluation of the Acceptability and Efficacy of One Medical Device in Venous Return in Comparison With a Control Group N/A
Completed NCT04292665 - Effects of Classical Massage and Benson Relaxation Exercise on Heart Failure Patients N/A
Recruiting NCT05681975 - Immunoglobulin G4 and Immunoglobulin E Antibodies in a Population With Adverse Reactions to Foodstuffs-related Symptoms
Completed NCT04169919 - Modified Treatment for Epidemic Keratoconjunctivitis (EKC) N/A
Recruiting NCT06436651 - Digital Storytelling in Symptom Management Pediatric Oncology N/A
Recruiting NCT04940780 - Integrative Oncology for Patient Symptoms N/A
Not yet recruiting NCT05837988 - Construction of Symptom Network in Maintenance Hemodialysis Patients
Recruiting NCT05092568 - Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
Recruiting NCT03968718 - PATIENT VOICES Integration of Systematic Assessment of Patient Reported Outcomes Within Clinical Oncology Practice N/A
Completed NCT05556707 - Symptom Clusters and Risk Factors of COVID-19 Patients
Completed NCT06153680 - Consumer Study for the Evaluation of the Usability and Efficacy of One Medical Device in Venous Return N/A
Completed NCT04873349 - Standardized Olive Leaf Capsules; as a Co-therapy in the Treatment of COVID-19 Patients N/A
Recruiting NCT06136221 - Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease N/A
Recruiting NCT05827406 - A Useful Support System for Psychiatric Diagnostics and Follow-up in Adult Psychiatry and Primary Care (ASPP)
Completed NCT06215339 - Diet Therapy in Hemodialysis Patients N/A